Owner Synaptic Pharmaceutical Corporation

Inventors Borowsky, Beth; Bonini, James; Jones, Kenneth; Gerald, Christophe

Agent Davies Collison Cave

Pub. Number AU-A-2004202118

Parent 61649

Filing date 14 May 2004

Wipo publication date 10 June 2004

C07H 021/04 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 005/06 Undifferentiated human, animal or plant cells, e.g. cell lines -

C12N 005/02 Undifferentiated human, animal or plant cells, e.g. cell lines - Propagation of single cells or cells in suspension

C07K 017/00 Carrier-bound or immobilised peptides

C07K 014/00 Peptides having more than 20 amino acids

C07K 001/00 General processes for the preparation of peptides

G01N 033/00 Investigating or analysing materials by specific methods not covered by groups

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

C12P 021/06 Preparation of peptides or proteins - produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

C12N 015/74 Mutation or genetic engineering - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

C12N 015/70 Mutation or genetic engineering - Vectors or expression systems specially adapted for E. coli

C12N 015/63 Mutation or genetic engineering - Introduction of foreign genetic material using vectors

C12N 015/09 Mutation or genetic engineering - Recombinant DNA-technology

C12N 015/00 Mutation or genetic engineering